Infarct Size Following Treatment With Second‐ Versus Third‐Generation P2Y(12) Antagonists in Patients With Multivessel Coronary Disease at ST‐Segment Elevation Myocardial Infarction in the CvLPRIT Study

BACKGROUND: Third‐generation P2Y(12) antagonists (prasugrel and ticagrelor) are recommended in guidelines on ST‐segment elevation myocardial infarction. Mechanisms translating their more potent antiplatelet activity into improved clinical outcomes versus the second‐generation P2Y(12) antagonist clop...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Jamal N., Greenwood, John P., Nazir, Sheraz A., Lai, Florence Y., Dalby, Miles, Curzen, Nick, Hetherington, Simon, Kelly, Damian J., Blackman, Daniel, Peebles, Charles, Wong, Joyce, Flather, Marcus, Swanton, Howard, Gershlick, Anthony H., McCann, Gerry P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937278/
https://www.ncbi.nlm.nih.gov/pubmed/27247336
http://dx.doi.org/10.1161/JAHA.116.003403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937278/
https://www.ncbi.nlm.nih.gov/pubmed/27247336
http://dx.doi.org/10.1161/JAHA.116.003403

Ejemplares similares